A phase 1b randomized, placebo-controlled clinical trial with SNF472 in haemodialysis patients.
作者信息
Salcedo Carolina, Joubert Pieter H, Ferrer Miguel D, Canals Ana Z, Maduell Francisco, Torregrosa Vicens, Campistol Josep Maria, Ojeda Raquel, Perelló Joan
机构信息
Laboratoris Sanifit, Palma, Spain.
Institute of Pharmaceutical Science, King's College, London, UK.
出版信息
Br J Clin Pharmacol. 2019 Apr;85(4):796-806. doi: 10.1111/bcp.13863. Epub 2019 Feb 19.
Abstract
摘要
相似文献
1
A phase 1b randomized, placebo-controlled clinical trial with SNF472 in haemodialysis patients.一项在血液透析患者中开展的使用SNF472的1b期随机、安慰剂对照临床试验。
Br J Clin Pharmacol. 2019 Apr;85(4):796-806. doi: 10.1111/bcp.13863. Epub 2019 Feb 19.
2
Slowing Progression of Cardiovascular Calcification With SNF472 in Patients on Hemodialysis: Results of a Randomized Phase 2b Study.血液透析患者中 SNF472 对心血管钙化进展的减缓作用：一项随机 2b 期研究的结果。
Circulation. 2020 Mar 3;141(9):728-739. doi: 10.1161/CIRCULATIONAHA.119.044195. Epub 2019 Nov 11.
3
First-time-in-human randomized clinical trial in healthy volunteers and haemodialysis patients with SNF472, a novel inhibitor of vascular calcification.在健康志愿者和血液透析患者中首次进行人体随机临床试验，评估 SNF472（一种新型血管钙化抑制剂）的安全性和药代动力学。
Br J Clin Pharmacol. 2018 Dec;84(12):2867-2876. doi: 10.1111/bcp.13752. Epub 2018 Oct 3.
4
Metastatic cardiac calcification in a patient with chronic renal failure who was undergoing hemodialysis: radiographic and CT findings.一名正在接受血液透析的慢性肾衰竭患者的转移性心脏钙化：影像学和CT表现
AJR Am J Roentgenol. 1998 Apr;170(4):903-5. doi: 10.2214/ajr.170.4.9530031.
5
Effects of Myo-inositol Hexaphosphate (SNF472) on Bone Mineral Density in Patients Receiving Hemodialysis: An Analysis of the Randomized, Placebo-Controlled CaLIPSO Study.肌醇六磷酸（SNF472）对血液透析患者骨密度的影响：随机、安慰剂对照 CaLIPSO 研究分析。
Clin J Am Soc Nephrol. 2021 May 8;16(5):736-745. doi: 10.2215/CJN.16931020. Epub 2021 Apr 7.
6
Improvement in wound healing, pain, and quality of life after 12 weeks of SNF472 treatment: a phase 2 open-label study of patients with calciphylaxis.SNF472 治疗 12 周后改善伤口愈合、疼痛和生活质量：伴有钙化防御患者的 2 期开放性标签研究。
J Nephrol. 2019 Oct;32(5):811-821. doi: 10.1007/s40620-019-00631-0. Epub 2019 Aug 10.
7
Calcinosis of the myocardium in chronic haemodialysed patients.慢性血液透析患者的心肌钙化
Pol Arch Med Wewn. 1985 Sep;74(3):213-6.
8
[Calcification of heart valves in hemodialized patients and their cardiosurgical correction].
Kardiol Pol. 2004 Aug;61(8):151-5; discussion 155.
9
Trial design and baseline characteristics of CaLIPSO: a randomized, double-blind placebo-controlled trial of SNF472 in patients receiving haemodialysis with cardiovascular calcification.CaLIPSO的试验设计与基线特征：一项针对接受血液透析且患有心血管钙化的患者进行的SNF472随机、双盲、安慰剂对照试验
Clin Kidney J. 2019 Oct 30;14(1):366-374. doi: 10.1093/ckj/sfz144. eCollection 2021 Jan.
10
How can the cardiac death rate be reduced in dialysis patients?如何降低透析患者的心源性死亡率？
Semin Dial. 2002 Jan-Feb;15(1):26-9. doi: 10.1046/j.1525-139x.2002.0006e.x.
引用本文的文献
1
Ten tips on how to deal with calciphylaxis patients.关于如何应对钙过敏症患者的十条建议。
Clin Kidney J. 2025 Apr 9;18(4):sfaf098. doi: 10.1093/ckj/sfaf098. eCollection 2025 Apr.
2
Hexasodium fytate for the treatment of calciphylaxis: a randomised, double-blind, phase 3, placebo-controlled trial with an open-label extension.植酸钠六钠治疗钙化防御：一项随机、双盲、3期、安慰剂对照试验及开放标签扩展研究
EClinicalMedicine. 2024 Aug 16;75:102784. doi: 10.1016/j.eclinm.2024.102784. eCollection 2024 Sep.
3
SNF472: a novel therapeutic agent for vascular calcification and calciphylaxis.SNF472：一种用于血管钙化和钙化防御的新型治疗药物。
J Nephrol. 2024 May;37(4):851-863. doi: 10.1007/s40620-024-01909-8. Epub 2024 Mar 21.
4
Hexasodium fytate exposure-response correlations in a randomized, placebo-controlled study of patients on dialysis with cardiovascular calcification.在一项针对患有心血管钙化的透析患者的随机、安慰剂对照研究中，植酸钠六钠的暴露-反应相关性。
Front Pharmacol. 2024 Feb 7;15:1325186. doi: 10.3389/fphar.2024.1325186. eCollection 2024.
5
Phytates as a natural source for health promotion: A critical evaluation of clinical trials.植酸盐作为促进健康的天然来源：对临床试验的批判性评估。
Front Chem. 2023 Apr 14;11:1174109. doi: 10.3389/fchem.2023.1174109. eCollection 2023.
6
New Therapeutics Targeting Arterial Media Calcification: Friend or Foe for Bone Mineralization?针对动脉中层钙化的新型疗法：对骨矿化而言是福是祸？
Metabolites. 2022 Apr 5;12(4):327. doi: 10.3390/metabo12040327.
7
Trial design and baseline characteristics of CaLIPSO: a randomized, double-blind placebo-controlled trial of SNF472 in patients receiving haemodialysis with cardiovascular calcification.CaLIPSO的试验设计与基线特征：一项针对接受血液透析且患有心血管钙化的患者进行的SNF472随机、双盲、安慰剂对照试验
Clin Kidney J. 2019 Oct 30;14(1):366-374. doi: 10.1093/ckj/sfz144. eCollection 2021 Jan.
8
A novel assay to measure calcification propensity: from laboratory to humans.一种新型的测量钙化倾向的检测方法：从实验室到人体。
Sci Rep. 2020 Oct 16;10(1):17578. doi: 10.1038/s41598-020-74592-x.
9
Mechanism of action of SNF472, a novel calcification inhibitor to treat vascular calcification and calciphylaxis.SNF472，一种新型的钙化抑制剂，用于治疗血管钙化和钙化防御的作用机制。
Br J Pharmacol. 2020 Oct;177(19):4400-4415. doi: 10.1111/bph.15163. Epub 2020 Aug 23.
10
Cardiovascular Calcification in Chronic Kidney Disease-Therapeutic Opportunities.慢性肾脏病中的心血管钙化——治疗机遇。
Toxins (Basel). 2020 Mar 14;12(3):181. doi: 10.3390/toxins12030181.
本文引用的文献
1
First-time-in-human randomized clinical trial in healthy volunteers and haemodialysis patients with SNF472, a novel inhibitor of vascular calcification.在健康志愿者和血液透析患者中首次进行人体随机临床试验，评估 SNF472（一种新型血管钙化抑制剂）的安全性和药代动力学。
Br J Clin Pharmacol. 2018 Dec;84(12):2867-2876. doi: 10.1111/bcp.13752. Epub 2018 Oct 3.
2
SNF472, a novel inhibitor of vascular calcification, could be administered during hemodialysis to attain potentially therapeutic phytate levels.SNF472，一种新型的血管钙化抑制剂，可在血液透析期间给药，以达到潜在的治疗性植酸盐水平。
J Nephrol. 2018 Apr;31(2):287-296. doi: 10.1007/s40620-018-0471-9. Epub 2018 Jan 19.
3
A novel pharmacodynamic assay to evaluate the effects of crystallization inhibitors on calcium phosphate crystallization in human plasma.一种新型药效学检测方法，用于评估结晶抑制剂对人血浆中磷酸钙结晶的影响。
Sci Rep. 2017 Jul 31;7(1):6858. doi: 10.1038/s41598-017-07203-x.
4
Vascular calcification: When should we interfere in chronic kidney disease patients and how?血管钙化：慢性肾脏病患者何时以及如何进行干预？
World J Nephrol. 2016 Sep 6;5(5):398-417. doi: 10.5527/wjn.v5.i5.398.
5
Electrocardiographic Abnormalities and QTc Interval in Patients Undergoing Hemodialysis.接受血液透析患者的心电图异常与QTc间期
PLoS One. 2016 May 12;11(5):e0155445. doi: 10.1371/journal.pone.0155445. eCollection 2016.
6
US Renal Data System 2015 Annual Data Report: Epidemiology of Kidney Disease in the United States.《美国肾脏数据系统2015年年报：美国肾脏疾病流行病学》
Am J Kidney Dis. 2016 Mar;67(3 Suppl 1):Svii, S1-305. doi: 10.1053/j.ajkd.2015.12.014.
7
Changes in QT interval before and after hemodialysis.血液透析前后QT间期的变化。
Caspian J Intern Med. 2013 Winter;4(1):590-4.
8
Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open-label 24-month randomized clinical trial.在新进入血液透析的患者中，司维拉姆与碳酸钙的比较：一项为期 24 个月、开放性、随机临床试验的结果。
Am J Kidney Dis. 2013 Oct;62(4):771-8. doi: 10.1053/j.ajkd.2013.03.023. Epub 2013 May 16.
9
Validation of an LC-MS bioanalytical method for quantification of phytate levels in rat, dog and human plasma.验证 LC-MS 生物分析方法用于定量检测大鼠、犬和人血浆中的植酸盐水平。
J Chromatogr B Analyt Technol Biomed Life Sci. 2013 Jun 1;928:146-54. doi: 10.1016/j.jchromb.2013.03.023. Epub 2013 Apr 8.
10
Protective effect of myo-inositol hexaphosphate (phytate) on bone mass loss in postmenopausal women.肌醇六磷酸（植酸）对绝经后妇女骨量流失的保护作用。
Eur J Nutr. 2013 Mar;52(2):717-26. doi: 10.1007/s00394-012-0377-6. Epub 2012 May 22.
Zotero 插件